I'm looking forward to hearing an update on the following topics..

Second Quarter Topics
Second manufacturing facility, and packaging line approvals
Naltrexone and Phendimetrazine products & commercialization
Phentermine 15, 30Mg
Bio equivalency studies
Cash flow neutral/ positive for fiscal 2013
Lodrane CR product(s)
Undisclosed generic pending approval